Neurotoxicity to DRG neurons varies between rodent strains treated with cisplatin and bortezomib

JOURNAL OF THE NEUROLOGICAL SCIENCES

卷:362

Article

Podratz, Jewel L.¹  Kulkarni, Amit²  Pleticha, Josef²  Kanwar, Rahul²  Beutler, Andreas S.²  Staff, Nathan P.¹  Windebank, Anthony J.¹ 

[1] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Med Oncol, Rochester, MN 55905 USA

关键词: Cisplatin;    Bortezomib;    Mouse strain;    Neurite outgrowth;    Neurotoxicity;    Genetic variations;   

DOI  :  10.1016/j.jns.2015.12.038

来源: Elsevier

【 摘 要 】

Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose limiting side effect that can lead to long-term morbidity. Approximately one-third of patients receiving chemotherapy with taxanes, vinca alkaloids, platinum compounds or proteasome inhibitors develop this toxic side effect. It is not possible to predict who will get CIPN, however, genetic susceptibility may play a role. We explored this hypothesis using an established in vitro dorsal root ganglia neurite outgrowth (DRG-NOG) assay to assess possible genetic influences for cisplatin-and bortezomib-induced neurotoxicity. Almost all previous in vitro studies have used rats or mice. We compared DRG-NOG between four genetically defined, inbred mouse strains (C57BL/6 J, DBA/2 J, BALB/cJ, and C3H/HeJ) and one rat strain (Sprague Dawley). Our studies found differences in cisplatin and bortezomib-induced neurotoxicity between mouse and rat strains and between the different mouse strains. C57BL/6 J and Balb/cJ DRG-NOG was more sensitive to cisplatin than DBA/2 J and C3H/HeJ DRG-NOG, and all mouse strains were more sensitive to cisplatin than rat. Bortezomib induced a biphasic dose response in DBA/2 J and C3H/H3J mice. C57BL/6 J DRG-NOG was most sensitive and Balb/cJ DRG-NOG was least sensitive to bortezomib. Our animal data supports the hypothesis that genetic background may play a role in CIPN and care must be taken when rodent models are used to better understand the contribution of genetics in patient susceptibility to CIPN. (C) 2016 Elsevier B.V. All rights reserved.

【 授权许可】

Free